Primetime Editorial

Mullen Automotive Is Making Beautiful Electric Cars, And Its Stock Looks Attractive Too ($MULN)

Mullen Automotive (NASDAQ: MULN) is doing things differently in the EV and clean energy sector. Most people wouldn’t think that’s necessary, believing that all companies in the sector are committed to bringing clean energy solutions to consumers and industry in a responsible manner. Truth be told, that’s not always the case. Many in the sector are rushing to market without the infrastructure to bring safe, reliable, and eco-friendly products to market. Publicly-traded Mullen Automotive, Inc. is doing the opposite. Mullen’s

Mullen Automotive Is Making Beautiful Electric Cars, And Its Stock Looks Attractive Too ($MULN) Read More »

KULR Technology Is Getting Bigger With An Acquisition That Expands Market Reach And Revenue-Generating Potential ($KULR)

KULR Technology Group Inc. (NYSE: KULR) stock is a roller coaster ride of late. But with Wall Street analysts modeling for appreciably higher share prices, the motion sickness may be worth the interest. And with several updates showing KULR’s potentially dominant position in the thermal management and energy storage markets, paying less attention to index-created volatility may be a wise consideration. With the global market for energy storage expected to generate as much as $554 billion in annual revenues by

KULR Technology Is Getting Bigger With An Acquisition That Expands Market Reach And Revenue-Generating Potential ($KULR) Read More »

Mainz Biomed’s Best-In-Class Cancer Screening Diagnostics Puts Explosive Growth In Its Crosshairs ($MYNZ)

Mainz Biomed (NASDAQ: MYNZ) stock gets pushed to degrees with low volume. But make no mistake, the trend in place is decidedly bullish. In fact, MYNZ stock has showed impressive performance in the worst of markets, decoupling from extraordinary small-cap biotech market weakness. Other day’s, MYNZ stock trades lower against a higher tape. So trying to time a purchase of MYNZ stock can be difficult. But for those playing long term, daily gyrations shouldn’t matter. The most important thing to

Mainz Biomed’s Best-In-Class Cancer Screening Diagnostics Puts Explosive Growth In Its Crosshairs ($MYNZ) Read More »

Silo Pharma May Change The Treatment Landscape For Neurological Disorders, Merging Traditional And Psychedelic Compounds ($SILO)

A new generation of patients can be powerful motivators for a pharmaceutical industry historically resistant to change. And if they don’t respect or act on the message given, they should expect that plenty around them will. But here’s the deal. Some are doing more than listening; they are taking advantage of emerging research to capitalize on what could be the most transformative periods in generations affecting the pharmaceutical sector. Silo Pharma (NASDAQ: SILO) wants to contribute to that change.  And

Silo Pharma May Change The Treatment Landscape For Neurological Disorders, Merging Traditional And Psychedelic Compounds ($SILO) Read More »

KULR Technology Assets And Contract Pipeline Should Have Its Stock Running With The Bulls…Here’s Why ($KULR)

KULR Technology Group Inc. (NYSE: KULR) stock is undervalued. Or, better said, it’s disconnected from its fair value when appraising the value from its significant asset portfolio, well-protected IP, and contract visibility with some of the largest global conglomerates. And the KULR story isn’t just a forward-looking one. Recent operational performance has helped KULR score record-setting revenues, strengthen its balance sheet, and expand its market reach into several potentially lucrative lithium-Ion battery-safety markets.  In other words, with greater business depth

KULR Technology Assets And Contract Pipeline Should Have Its Stock Running With The Bulls…Here’s Why ($KULR) Read More »

Mainz Biomed Stock Is Catching A Bid; Cancer Screening Diagnostics Tap Into Billion Dollar Potential ($MYNZ)

Mainz Biomed (NASDAQ: MYNZ) may be doing a bit of a zig zag in recent trading but at the end of the day its stock has done something that few micro-cap biotech stocks have been able to match- trade higher. And with its decoupling putting a technical uptrend into motion, the best part of recent trading could be that it’s the precursor of more to come. In fact, the more this thinly traded molecular genetics diagnostics company makes it to

Mainz Biomed Stock Is Catching A Bid; Cancer Screening Diagnostics Tap Into Billion Dollar Potential ($MYNZ) Read More »

KULR’s Milestones Reached Set Up A Potentially Powerful Q4 Rally ($KULR)

If there is one thing to know about KULR Technology Group Inc. (NYSE: KULR), it’s this- they have positioned themselves to dominate the lithium-Ion battery safety market. And the better news; results from that work are showing, with revenues scoring record levels, costs decreasing, and expansion of its innovative technology into several high-volume, high-dollar markets. In other words, while many viewed KULR as a premier play to get exposure into the massive EV battery safety market, they now have much

KULR’s Milestones Reached Set Up A Potentially Powerful Q4 Rally ($KULR) Read More »

Mainz Biomed Decouples From Weaker Markets, Investors Focused On Best-In-Class Cancer Screening Diagnostics ($MYNZ)

Mainz Biomed (NASDAQ: MYNZ) stock may present a value investment opportunity too good to ignore. In fact, a move higher is the likely path of least resistance for this thinly traded molecular genetics diagnostics company. They have a well-fortified balance sheet, best-in-class early cancer detection tests, and a management team that’s part of a Who’s Who list in biotech management fueling that proposition. But there’s more to validate that case. Like most smallcap biotechs in this turbulent market, MYNZ stock

Mainz Biomed Decouples From Weaker Markets, Investors Focused On Best-In-Class Cancer Screening Diagnostics ($MYNZ) Read More »

Cosmos Health Is Getting Bigger, Signs Distribution Deal To Expedite Growth In Germany And Austria ($COSM)

Smallcap stocks may be under pressure. But not all are being pulled down by the decidedly bearish sentiment. Cosmos Health (NASDAQ: COSM), formerly Cosmos Holdings, is decoupling from the weakness and is doing so on merit, not hype. In fact, its recent 28% surge to $0.46 in September is supported by another batch of excellent news, which added to an already compelling value proposition resulting from several milestones reached earlier this year. These included a triple-digit percentage increase in EBITDA,

Cosmos Health Is Getting Bigger, Signs Distribution Deal To Expedite Growth In Germany And Austria ($COSM) Read More »

Recharge Resources

Recharge Resources Receives Approvals To Drill At Pocitos 1 Project; Follows Expedited Development At Georgia Lake And West Lithium Properties ($RECHF)

Recharge Resources Ltd. (RR: CSE) (RECHF: OTC) (SL5: Frankfurt) is consolidating at multi-month highs, bumping against the $0.40 level, it’s highest point since April 2022. The move comes after a string of good news. Last week, Recharge announced receiving approval from Argentina’s Dept of Mines for its imminent drilling of a production diameter well at its “Pocitos 1” Salar Lithium Brine Project in Salta, Argentina. That news followed the announcement of plans to expedite development at its Georgia Lake and

Recharge Resources Receives Approvals To Drill At Pocitos 1 Project; Follows Expedited Development At Georgia Lake And West Lithium Properties ($RECHF) Read More »